PIOMBINO DESE, Italy–(BUSINESS WIRE)–Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2025. Fourth Quarter and Full Year 2025 Highlights (comparisons to prior-year periods) For the fourth quarter of 2025, revenue increased 5% (7% on a constant currency basis) to €346.5 million,
Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins
